Previous work in yeast has suggested that modification of tRNAs, in particular
uridine bases in the anticodon wobble position (U34), is linked to TOR (target
of rapamycin) signaling. Hence, U34 modification mutants were found to be
hypersensitive to TOR inhibition by rapamycin. To study whether this involves
inappropriate TOR signaling, we examined interaction between mutations in TOR
pathway genes (tip41∆, sap190∆,
ppm1∆, rrd1∆) and U34 modification defects
(elp3∆, kti12∆,
urm1∆, ncs2∆) and found the rapamycin
hypersensitivity in the latter is epistatic to drug resistance of the former.
Epistasis, however, is abolished in tandem with a gln3∆
deletion, which inactivates transcription factor Gln3 required for TOR-sensitive
activation of NCR (nitrogen catabolite repression) genes. In line with nuclear
import of Gln3 being under control of TOR and dephosphorylation by the Sit4
phosphatase, we identify novel TOR-sensitive sit4 mutations that confer
rapamycin resistance and importantly, mislocalise Gln3 when TOR is inhibited.
This is similar to gln3∆ cells, which abolish the rapamycin
hypersensitivity of U34 modification mutants, and suggests TOR deregulation due
to tRNA undermodification operates through Gln3. In line with this, loss of U34
modifications (elp3∆, urm1∆) enhances nuclear
import of and NCR gene activation (MEP2, GAP1)
by Gln3 when TOR activity is low. Strikingly, this stimulatory effect onto Gln3
is suppressed by overexpression of tRNAs that usually carry the U34
modifications. Collectively, our data suggest that proper TOR signaling requires
intact tRNA modifications and that loss of U34 modifications impinges on the
TOR-sensitive NCR branch via Gln3 misregulation.